Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

RenovoRx, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MOUNTAIN VIEW, CALIF., JULY 29, 2026 (GLOBE NEWSWIRE) -- RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH  , A PATENTED, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED THAT IT WILL HOST ITS SECOND QUARTER 2026 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS CONFERENCE CALL ON AUGUST 12, 2026, AT 4:30 P.M. ET.

RENOVORX TO HOST SECOND QUARTER 2026 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS CONFERENCE CALL ON AUGUST 12TH AT 4:30 P.M. ET

MOUNTAIN VIEW, CALIF., JUNE 11, 2026 (GLOBE NEWSWIRE) -- RENOVORX, INC.

RENOVORX HIGHLIGHTS PEER-REVIEWED PUBLICATION SUPPORTING INTRA-ARTERIAL GEMCITABINE DELIVERY VIA TAMP IN LOCALLY ADVANCED PANCREATIC CANCER

MOUNTAIN VIEW, CALIF., JUNE 04, 2026 (GLOBE NEWSWIRE) -- RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH  , A NOVEL, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED THAT CHIEF EXECUTIVE OFFICER, SHAUN BAGAI, WILL PRESENT AT THE IACCESS ALPHA VIRTUAL BEST IDEAS SUMMER INVESTMENT CONFERENCE 2026, BEING HELD JUNE 23-24, 2026.

RENOVORX CEO, SHAUN BAGAI, TO PRESENT AT THE IACCESS ALPHA VIRTUAL BEST IDEAS SUMMER INVESTMENT CONFERENCE 2026 ON JUNE 23RD

THIRD FDA ORPHAN DRUG DESIGNATION CONTINUES TO ADVANCE RENOVORX'S THERAPEUTIC ONCOLOGY PIPELINE AND PROVIDES SEVEN YEARS OF MARKET EXCLUSIVITY THIRD FDA ORPHAN DRUG DESIGNATION CONTINUES TO ADVANCE RENOVORX'S THERAPEUTIC ONCOLOGY PIPELINE AND PROVIDES SEVEN YEARS OF MARKET EXCLUSIVITY

RENOVORX ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED: OXALIPLATIN FOR THE TREATMENT OF PANCREATIC CANCER

SUB-STUDY FROM ONGOING PHASE III TIGER-PAC CLINICAL TRIAL SUPPORTS TAMP FOR TARGETED INTRA-ARTERIAL DELIVERY OF GEMCITABINE, DEMONSTRATING POTENTIAL TO INCREASE LOCAL DRUG POTENCY AND REDUCE SYSTEMIC EXPOSURE AND COMMON SIDE EFFECTS

RENOVORX ANNOUNCES PROMISING PHARMACOKINETIC DATA USING THE TAMP PLATFORM PRESENTED AT THE 2026 ASCO ANNUAL MEETING

MOUNTAIN VIEW, CALIF., MAY 19, 2026 (GLOBE NEWSWIRE) -- RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH  , A NOVEL, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED THAT CHIEF EXECUTIVE OFFICER SHAUN BAGAI AND CHIEF FINANCIAL OFFICER MARK VOLL WILL PARTICIPATE IN THE ALLIANCE GLOBAL PARTNERS (AGP) ANNUAL HEALTHCARE COMPANY SHOWCASE, HOSTED BY SCOTT HENRY, AGP'S MANAGING DIRECTOR AND SENIOR HEALTHCARE ANALYST, ON MAY 20, 2026.

RENOVORX TO PRESENT AT THE ALLIANCE GLOBAL PARTNERS VIRTUAL ANNUAL HEALTHCARE COMPANY SHOWCASE ON MAY 20TH

Q1 2026 REVENUE OF $563,000 TOTALS OVER 50% OF FULL YEAR 2025 TOTAL REVENUE ACTIVE COMMERCIAL CANCER CENTER CUSTOMERS EXPAND TO 16 WITH GROWING SALES PIPELINE, ACCELERATING ADOPTION OF THE TAMP THERAPY PLATFORM ENABLED BY THE RENOVOCATH  DEVICE PHASE III TIGER-PAC TRIAL ADVANCES TOWARD COMPLETION WITH FULL ENROLLMENT EXPECTED IN JUNE 2026 ENDED FIRST QUARTER WITH $12.4 MILLION IN CASH, SUFFICIENT TO FUND OPERATIONS INTO AT LEAST THE SECOND HALF OF 2027 MANAGEMENT TO HOST CONFERENCE CALL TODAY AT 4:30 P.M. ET MOUNTAIN VIEW, CALIF.

RENOVORX REPORTS RECORD FIRST QUARTER 2026: INCREASING REVENUE BY 136% QUARTER-OVER-QUARTER

MOUNTAIN VIEW, CALIF., APRIL 29, 2026 (GLOBE NEWSWIRE) -- RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH  , A PATENTED, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED THAT IT WILL HOST ITS FIRST QUARTER 2026 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS CONFERENCE CALL ON MAY 14, 2026, AT 4:30 PM ET. ADDITIONAL DETAILS WILL BE AVAILABLE ON THE INVESTOR RELATIONS SECTION OF THE COMPANY'S WEBSITE AT HTTPS://IR.RENOVORX.COM/.

RENOVORX TO HOST FIRST QUARTER 2026 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS CONFERENCE CALL ON MAY 14TH AT 4:30 PM ET

MOUNTAIN VIEW, CALIF., APRIL 23, 2026 (GLOBE NEWSWIRE) -- RENOVORX, INC.

RENOVORX ANNOUNCES PHARMACOKINETIC AND PHARMACODYNAMIC DATA ABSTRACT SUPPORTING THE TAMP THERAPY PLATFORM ACCEPTED FOR PRESENTATION AT THE 2026 ASCO ANNUAL MEETING

DATA SHOWS TAMP TO BE A PROMISING APPROACH FOR LOCAL DELIVERY OF GEMCITABINE WITH REDUCED SYSTEMIC TOXICITY IN PATIENTS DIAGNOSED WITH LOCALLY ADVANCED PANCREATIC CANCER

RenovoRx, Inc.

RNXT

Price

Financial Reports

No items found.

Press Releases

RenovoRx, Inc.

RNXT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

RNXT